Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Robbins Geller Rudman & Dowd LLPINVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SIONRobbins Geller Rudman & Dowd LLP is investigating potential violations of United States federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you any have information that could assist in the Sionna Therapeutics...
- City of Irvine and SpyGlass PharmaSpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D SpaceFuture portfolio expansion will advance a new era of ophthalmic care while driving continued growth of Irvine's MedTech and life sciences sector. — SpyGlass Pharma, a biopharmaceutical clinical-stage company dedicated to transforming treatment...
- Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineCompanies: PfizerPfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.1
- Pfizer Inc.Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineCompanies: PfizerNEW YORK & MAINZ, Germany, August 27, 2026--Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying cond
- IQVIAIQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and HealthcareCompanies: IQVIA Holdings, Inc.RESEARCH TRIANGLE PARK, N.C., August 27, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial execution
- Water Tower Research Publishes Initiation of Coverage Report on PharmAla Biotech Holdings, Inc., “Monetizing Regulatory Advantage Through IP and Data”August 27, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on PharmAla Biotech Holdings, Inc. (CSE:MDMA/OTC:MDXXF) titled, “Monetizing Regulatory Advantage Through IP and Data”. The report can be accessed here. PharmAla Biotech […]
- The Law Offices of Frank R. Cruz, Los AngelesAardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitThe Law Offices of Frank R. Cruz announces that investors with losses related to Aardvark Therapeutics, Inc. (AARD) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK...
- FDA Issues Emergency Use Authorization for Generic Drug to Prevent New World Screwworm in CattleThe U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Bimectin (ivermectin) injection for the prevention of New World screwworm (NWS) infestations (myiasis) in cattle when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound – advancing the Trump Administration's goal of safeguarding American agriculture from NWS. Bimectin injection is not authorized for use in lactating dairy cows or in calves that will be processed for veal.
- Oryon Cell TherapiesOryon Cell Therapies Appoints Kenny Choi, Ph.D. as Chief Technical OfficerWATERTOWN, Mass., August 27, 2026--Oryon Cell Therapies ("Oryon"), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegenerative disorders, today announced the appointment of Kenny Choi, Ph.D., as Chief Technical Officer (CTO). Dr. Choi will lead Oryon’s technical operations and Chemistry, Manufacturing, and Controls (CMC) strategy, including transfer of the manufacturing process for the company’s autologo
- The World's Leading Minds in Biotechnology Will Meet in Riyadh This SeptemberRIYADH, KSA, Aug 28, 2026 - The Riyadh Global Medical Biotechnology Summit has published the scientific program for its fourth edition, and the names on it belong to the people currently deciding what medicine will be able to do in the next twenty years. Sixty confirmed speakers and moderators from eleven countries are named across three days, from 14 to 16 September 2026, at the Sofitel Riyadh Hotel and Convention Centre. Among them are Prof. Jin-Soo Kim of KAIST, whose work on mitochondrial DNA editing reaches beyond CRISPR; Dr. Matthew H. Porteus of Stanford University, engineering genetic circuits into cell-based medicines; Dr. Alex Shalek of MIT; Prof. Vijay Kuchroo of Harvard Medical School; Prof. Keith T. Flaherty of the Massachusetts General Hospital Cancer Center and President of the American Association for Cancer Research; Prof. George F. Gao of the Chinese Academy of Sciences; President Mitsuo Ochi of Hiroshima University; and Dr. Zdenko Herceg of the International Agency for Research on Cancer. They are joined by the people who move science into the world. Dr. Steve Yang, Co-CEO of WuXi AppTec, and Mr. Alec Reynolds of Flagship Pioneering open the program on global partnership. Mr. Kasim Kutay, Chief Executive Officer of Novo Holdings, speaks on where capital should go next. Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, delivers the closing keynote. Alongside them stand the Saudi institutions building a biotechnology sector in real time: KAIMRC, Lifera, HUMAIN, SPIMACO, KAUST, the Saudi Food and Drug Authority, and Astronaut Rayyanah Barnawi on what the human immune system does in space. The program runs across six tracks: artificial intelligence in biotechnology, multi-omics, biotech investment, immunology, bioengineering and synthetic biology, and biotech workforce development. Its defining feature is that discovery and delivery share the same stage. Genome editing and population genomics sit beside regulation, domestic manufacturing, and procurement, and in several sessions the scientists and the regulators are on the same panel. That is the premise of the Kingdom's National Biotechnology Strategy, which targets $34.6 billion in non-oil GDP from biotechnology by 2040: a discovery is worth only as much as the system available to carry it to a patient. "Biotechnology is where the health of every nation will be decided over the next twenty years. Saudi Arabia has chosen not to watch that happen from a distance. We are building the laboratories, the manufacturing, the regulatory ecosystems, and above all, the bio-workforce talent. And we are building it in partnership with the world, under one roof. That is what this Summit is for. Its themes highlight where medicine and biotechnology converge to shape the future of biosciences. Discoveries and breakthroughs are transforming how we care for patients. The diversity of emerging technologies and therapies is creating significant opportunities to explore, advance, invest, and translate scientific progress into better health outcomes. Please join us in Riyadh this September." H.E. Prof. Bandar bin Abdulmohsen Al-Knawy, Chief Executive Officer of Health Affairs, Ministry of National Guard, and President, King Saud bin Abdulaziz University for Health Sciences The Summit is organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Abdullah International Medical Research Center (KAIMRC) and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), with the Ministry of Investment and Invest Saudi serving as strategic partners. The fourth edition is expected to welcome more than 15,000 visitors, over 200 biotechnology and healthcare brands, and delegations from more than 70 countries, under the theme Building the Foundations of Biotechnology Excellence. The full scientific program is attached and available at rgmbs.org, where registration is open for delegates, exhibitors, and industry partners. Follow the Summit at #RGMBS2026. For further information regarding summit programing visit: https://rgmbs.org/program#conference-agenda About the Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition takes place from 14 to 16 September 2026 in Riyadh. For Media Inquiry Email: [email protected] Telephone: +966 559 810 777
- ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the First Half of 2026TOULOUSE, France & FULLERTON, Calif., August 27, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I-based technology platform, today provides an update on its activity and cash position as of June 30, 2026.
- The World's Leading Minds in Biotechnology Will Meet in Riyadh This SeptemberRIYADH, KSA, Aug 28, 2026 - The Riyadh Global Medical Biotechnology Summit has published the scientific program for its fourth edition, and the names on it belong to the people currently deciding what medicine will be able to do in the next twenty years. Sixty confirmed speakers and moderators from eleven countries are named across three days, from 14 to 16 September 2026, at the Sofitel Riyadh Hotel and Convention Centre. Among them are Prof. Jin-Soo Kim of KAIST, whose work on mitochondrial DNA editing reaches beyond CRISPR; Dr. Matthew H. Porteus of Stanford University, engineering genetic circuits into cell-based medicines; Dr. Alex Shalek of MIT; Prof. Vijay Kuchroo of Harvard Medical School; Prof. Keith T. Flaherty of the Massachusetts General Hospital Cancer Center and President of the American Association for Cancer Research; Prof. George F. Gao of the Chinese Academy of Sciences; President Mitsuo Ochi of Hiroshima University; and Dr. Zdenko Herceg of the International Agency for Research on Cancer. They are joined by the people who move science into the world. Dr. Steve Yang, Co-CEO of WuXi AppTec, and Mr. Alec Reynolds of Flagship Pioneering open the program on global partnership. Mr. Kasim Kutay, Chief Executive Officer of Novo Holdings, speaks on where capital should go next. Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, delivers the closing keynote. Alongside them stand the Saudi institutions building a biotechnology sector in real time: KAIMRC, Lifera, HUMAIN, SPIMACO, KAUST, the Saudi Food and Drug Authority, and Astronaut Rayyanah Barnawi on what the human immune system does in space. The program runs across six tracks: artificial intelligence in biotechnology, multi-omics, biotech investment, immunology, bioengineering and synthetic biology, and biotech workforce development. Its defining feature is that discovery and delivery share the same stage. Genome editing and population genomics sit beside regulation, domestic manufacturing, and procurement, and in several sessions the scientists and the regulators are on the same panel. That is the premise of the Kingdom's National Biotechnology Strategy, which targets $34.6 billion in non-oil GDP from biotechnology by 2040: a discovery is worth only as much as the system available to carry it to a patient. "Biotechnology is where the health of every nation will be decided over the next twenty years. Saudi Arabia has chosen not to watch that happen from a distance. We are building the laboratories, the manufacturing, the regulatory ecosystems, and above all, the bio-workforce talent. And we are building it in partnership with the world, under one roof. That is what this Summit is for. Its themes highlight where medicine and biotechnology converge to shape the future of biosciences. Discoveries and breakthroughs are transforming how we care for patients. The diversity of emerging technologies and therapies is creating significant opportunities to explore, advance, invest, and translate scientific progress into better health outcomes. Please join us in Riyadh this September." H.E. Prof. Bandar bin Abdulmohsen Al-Knawy, Chief Executive Officer of Health Affairs, Ministry of National Guard, and President, King Saud bin Abdulaziz University for Health Sciences The Summit is organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Abdullah International Medical Research Center (KAIMRC) and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), with the Ministry of Investment and Invest Saudi serving as strategic partners. The fourth edition is expected to welcome more than 15,000 visitors, over 200 biotechnology and healthcare brands, and delegations from more than 70 countries, under the theme Building the Foundations of Biotechnology Excellence. The full scientific program is attached and available at rgmbs.org, where registration is open for delegates, exhibitors, and industry partners. Follow the Summit at #RGMBS2026. For further information regarding summit programing visit: https://rgmbs.org/program#conference-agenda About the Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition takes place from 14 to 16 September 2026 in Riyadh. For Media Inquiry Email: [email protected] Telephone: +966 559 810 777